OBI-998 is an immunotherapeutic antibody-drug conjugate (ADC) targeting SSEA-4, a tumor associated carbohydrate antigen highly expressed in many cancers. Its novel linker technology allows patients to benefit from the specificity of an antibody as well as highly potent small molecule cytotoxic drug.Compared to conventional chemotherapeutic drugs, its SSEA-4-specific monoclonal antibody targets tumors with such specific antigen expression. Site-specific release of cytotoxic drug payload at the targeted sites can shrink or eradicate tumors, while potentially reducing damage to normal cells and,lowering the chance of side effects.
OBI-998 related patent (PCT) has been publicly disclosed.
Preclinical Proof-of-Concept (POC) has been completed. Follow-up evaluation of linker stability, pharmacodynamics and biodistribution are underway.